VCNX's Business Model
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.vaccinex.com |
| CEO (Chief Executive Officer) | Maurice Zauderer |
| Number of Employees | |
| IPO date | August 9, 2018 |
VCNX Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 1895 Mount Hope Avenue |
| City | Rochester |
| State | NY |
| Phone | 585 271 2700 |
| Zip Code | 14620 |
| Other Identifiers | |
| CIK | 0001205922 |
| ISIN | US9186403013 |
| CUSIP | 918640103 |
| Open | 0.73 |
| Previous Close | 0.75 |
| Volume | 1.13 Thou. |
| Average Volume | 1.54 Thou. |
| Day’s Range | 0.58 – 0.73 |
| 52 Week Range | 0.25-8.9 |
| MA (50) | 0.8204 |
| MA (200) | 1.7287 |
| Market Cap | 1.55 Mil. |
| Shares Out. | 2.68 Mil. |
| Earnings Date | Aug 12, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
